Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ArriVent BioPharma (AVBP) Payables (2023 - 2026)

ArriVent BioPharma has reported Payables over the past 4 years, most recently at $8.7 million for Q1 2026.

  • Quarterly results put Payables at $8.7 million for Q1 2026, up 99.98% from a year ago — trailing twelve months through Mar 2026 was $8.7 million (up 99.98% YoY), and the annual figure for FY2025 was $5.9 million, up 56.9%.
  • Payables reached $8.7 million in Q1 2026 per AVBP's latest filing, up from $5.9 million in the prior quarter.
  • Across five years, Payables topped out at $8.7 million in Q1 2026 and bottomed at $3.8 million in Q4 2024.
  • Median Payables over the past 4 years was $4.4 million (2023), compared with a mean of $5.0 million.
  • The largest annual shift saw Payables fell 16.55% in 2024 before it skyrocketed 99.98% in 2026.
  • Over 4 years, Payables stood at $4.5 million in 2023, then fell by 16.55% to $3.8 million in 2024, then surged by 56.9% to $5.9 million in 2025, then surged by 47.07% to $8.7 million in 2026.
  • Business Quant data shows Payables for AVBP at $8.7 million in Q1 2026, $5.9 million in Q4 2025, and $5.9 million in Q3 2025.